Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 701 to 750 of 881

TitleReference numberPublishedLast updated
Bortezomib for previously untreated mantle cell lymphomaTA370
Vortioxetine for treating major depressive episodesTA367
Ledipasvir–sofosbuvir for treating chronic hepatitis CTA363
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis CTA365
Tolvaptan for treating autosomal dominant polycystic kidney diseaseTA358
Idelalisib for treating chronic lymphocytic leukaemiaTA359
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal)TA362
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapyTA352
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)TA353
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolismTA354
Naloxegol for treating opioid‑induced constipationTA345
Aflibercept for treating diabetic macular oedemaTA346
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancerTA347
Everolimus for preventing organ rejection in liver transplantationTA348
Secukinumab for treating moderate to severe plaque psoriasisTA350
Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal)TA351
Omalizumab for previously treated chronic spontaneous urticariaTA339
Vedolizumab for treating moderately to severely active ulcerative colitisTA342
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolismTA341
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemiaTA343
Empagliflozin in combination therapy for treating type 2 diabetesTA336
Rifaximin for preventing episodes of overt hepatic encephalopathyTA337
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndromeTA335
Sofosbuvir for treating chronic hepatitis CTA330
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatmentTA333
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal)TA334
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapyTA329
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanomaTA269
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolismTA327
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapyTA323
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular blockTA324
Nalmefene for reducing alcohol consumption in people with alcohol dependenceTA325
Imatinib for the adjuvant treatment of gastrointestinal stromal tumoursTA326
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular blockTA88
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanomaTA321
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosisTA320
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimenTA316
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromesTA317
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanomaTA319
Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failureTA314
Canagliflozin in combination therapy for treating type 2 diabetesTA315
Teriflunomide for treating relapsing–remitting multiple sclerosisTA303
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancerTA310
Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantationTA311
Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitisTA308
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapyTA307
Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hipTA304
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusionTA305
Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphomaTA306
Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis CTA106

Results per page

  1. 10
  2. 25
  3. 50
  4. All